Feedback Regulatory News (FDBK)

6 November 2015

Feedback plc

("Feedback" or the "Company")

Directorate Change

Further to the publication of Feedback's final results earlier today, the Company announces the appointment to the Board of Dr Balaji Ganeshan, Mike Hayball and Dr Alex Menys.

Disclosures under Schedule 2 of the AIM Rules

Dr Ganeshan, aged 33, holds or has held the following directorships and/or partnerships in the previous five years:

Dr Ganeshan holds 2,860,000 ordinary shares in the Company, equivalent to 1.40% of the issued ordinary share capital of the Company and 3,575,000 warrants of which, 715,000 warrants are exercisable at a price of 1.25p per share and the remaining 2,860,000 are exercisable at 3p per share.

No additional information relating to Dr Ganeshan is required to be disclosed under Rule 17 or Schedule 2 paragraph (g) of the AIM Rules for Companies.

Michael Peter Hayball, aged 48, holds or has held the following directorships and/or partnerships in the previous five years:

Mr Hayball holds 5,670,000 ordinary shares in the Company, equivalent to 2.78% of the issued ordinary share capital of the Company and 5,200,000 options of which, 1,200,000 options are exercisable at a price of 1.25p per share, 2,000,000 may be exercised at 3p per share and the remaining 2,000,000 options are exercisable at 5p per share.

No additional information relating to Mr Hayball is required to be disclosed under Rule 17 or Schedule 2 paragraph (g) of the AIM Rules for Companies.

Dr Alexander Henry Menys, aged 29, holds or has held the following directorships and/or partnerships in the previous five years:

Dr Menys does not hold any ordinary shares in the Company.

No additional information relating to Dr Menys is required to be disclosed under Rule 17 or Schedule 2 paragraph (g) of the AIM Rules for Companies.

For further information contact:

Notes to editors:

TexRAD (is a novel sophisticated imaging risk stratification research tool that analyses the textures in existing radiological scans. This research software application analyses textures, detecting and measuring tumour heterogeneity (complexity) from these images, revealing more information from medical images than it is currently possible to see with the naked eye. Research to date has shown that TexRAD could potentially assist the clinician (as an 'Imaging Biomarker') in confident decision-making: assessing the prognosis, disease severity (e.g. risk of metastases) and response evaluation of patients with cancer. Currently TexRAD research has shown great potential in many different oncological sites, including, colorectal, breast, lung, prostate, oesophageal, head & neck, lymphoma, liver and renal cancers and could potentially be employed as a heterogeneity assessing tool in the era of 'Precision and Personalized Medicine'. TexRAD is manufactured under licence by the ISO 13485 certified company Cambridge Computed Imaging Ltd, a subsidiary of Feedback plc. More information is available on www.fbk.com and www.texrad.com.